{"id":"metformin-blinded","safety":{"commonSideEffects":[{"rate":"20–30","effect":"Gastrointestinal disturbance (nausea, diarrhea, abdominal discomfort)"},{"rate":"3–5","effect":"Metallic taste"},{"rate":"10–30","effect":"Vitamin B12 deficiency"},{"rate":"<0.1","effect":"Lactic acidosis (rare, in renal impairment)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Metformin is a biguanide that primarily works by decreasing gluconeogenesis in the liver and enhancing peripheral glucose uptake and utilization. It activates AMPK, a key metabolic regulator, which suppresses mTORC1 signaling and reduces hepatic glucose output. Additionally, metformin may improve insulin sensitivity in muscle and adipose tissue, making it effective for glycemic control in type 2 diabetes.","oneSentence":"Metformin reduces hepatic glucose production and improves insulin sensitivity by activating AMP-activated protein kinase (AMPK).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:20:57.169Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"},{"name":"Prediabetes (prevention of progression to type 2 diabetes)"},{"name":"Polycystic ovary syndrome (PCOS)"}]},"trialDetails":[{"nctId":"NCT06120881","phase":"EARLY_PHASE1","title":"Precision Dosing of Metformin in Youth With T2D","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2024-04-25","conditions":"Type 2 Diabetes","enrollment":20},{"nctId":"NCT07272967","phase":"PHASE4","title":"Metformin in Preventing Secondary Gliosis Following Acute Thoraco-Lumbar Spinal Cord Injury","status":"NOT_YET_RECRUITING","sponsor":"Badr University","startDate":"2026-01-01","conditions":"Spinal Cord Injury (SCI)","enrollment":34},{"nctId":"NCT06393348","phase":"PHASE2","title":"Efficacy and Safety of HRS-7535 Tablets in T2DM Subjects Poorly Controlled With Metformin and SGLT2i.","status":"COMPLETED","sponsor":"Shandong Suncadia Medicine Co., Ltd.","startDate":"2024-05-17","conditions":"Type 2 Diabetes","enrollment":155},{"nctId":"NCT06490874","phase":"","title":"Continuous Glucose Monitoring (CGM) Substudy of the DECIDE RCT","status":"WITHDRAWN","sponsor":"Ohio State University","startDate":"2025-09","conditions":"Gestational Diabetes Mellitus, Pregnancy, High Risk","enrollment":""},{"nctId":"NCT05949008","phase":"PHASE4","title":"Effect of Metformin, a Drug Used to Treat Diabetes, vs Placebo","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, Los Angeles","startDate":"2023-11-22","conditions":"NIDDM, Obesity","enrollment":150},{"nctId":"NCT06033131","phase":"PHASE3","title":"PI4 - A Trial Assessing Metformin to Prolong Gestation in Preterm Preeclampsia","status":"RECRUITING","sponsor":"Lina Bergman","startDate":"2024-01-19","conditions":"Preeclampsia","enrollment":294},{"nctId":"NCT06000462","phase":"PHASE4","title":"The Effect of Dapagliflozin on Weight Loss in Obese Adults Without Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Oman Ministry of Health","startDate":"2024-04-22","conditions":"Obesity, Dapagliflozin Adverse Reaction, Weight Loss","enrollment":150},{"nctId":"NCT06589765","phase":"PHASE3","title":"A Study of HRS-7535 Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequately Controlled With Metformin","status":"RECRUITING","sponsor":"Shandong Suncadia Medicine Co., Ltd.","startDate":"2024-09-27","conditions":"Type 2 Diabetes","enrollment":800},{"nctId":"NCT06576375","phase":"PHASE3","title":"Efficacy of Dapagliflozin Versus Metformin in Polycystic Ovary Syndrome","status":"RECRUITING","sponsor":"Future University in Egypt","startDate":"2024-09-02","conditions":"Polycystic Ovary Syndrome","enrollment":70},{"nctId":"NCT06244550","phase":"NA","title":"Clinical Trials Using HepatoKeeper Herbal Essentials to Treat Non-alcoholic Fatty Liver Disease and Metabolic Factors","status":"COMPLETED","sponsor":"Taipei City Hospital","startDate":"2021-09-22","conditions":"Non-alcoholic Fatty Liver Disease, Liver Fibrosis, Liver Injury","enrollment":60},{"nctId":"NCT00736385","phase":"PHASE4","title":"Metformin for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD)","status":"TERMINATED","sponsor":"Duke University","startDate":"2009-04","conditions":"Fatty Liver","enrollment":11},{"nctId":"NCT06128967","phase":"PHASE3","title":"A Multicenter, Adaptive, Randomized, doublE-blinded, Placebo-controlled Study in Participants With Long COVID-19: The REVIVE Trial","status":"UNKNOWN","sponsor":"Cardresearch","startDate":"2023-10-18","conditions":"Long COVID-19 Syndrome, Chronic Fatigue Syndrome","enrollment":1500},{"nctId":"NCT04504396","phase":"PHASE3","title":"Safety and Efficacy of PB-119 in Subjects With Type 2 Diabetes and Not Well-controlled by Metformin Monotherapy","status":"COMPLETED","sponsor":"PegBio Co., Ltd.","startDate":"2020-06-23","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":620},{"nctId":"NCT01779362","phase":"PHASE3","title":"RISE Adult Medication Study","status":"COMPLETED","sponsor":"RISE Study Group","startDate":"2013-04","conditions":"Prediabetes, Type 2 Diabetes","enrollment":267},{"nctId":"NCT05759897","phase":"PHASE2","title":"A 16 Week Study of HRS-7535 in Adults With Type 2 Diabetes Mellitus","status":"UNKNOWN","sponsor":"Shandong Suncadia Medicine Co., Ltd.","startDate":"2023-02-28","conditions":"Type 2 Diabetes","enrollment":180},{"nctId":"NCT00134303","phase":"PHASE4","title":"Trial Comparing Metformin Versus Placebo in Non Alcoholic Steatohepatitis (NASH) Patients Receiving Bariatric Surgery for Obesity","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2005-06","conditions":"Obesity","enrollment":65},{"nctId":"NCT02201381","phase":"PHASE3","title":"Study of the Safety, Tolerability and Efficacy of Metabolic Combination Treatments on Cancer","status":"WITHDRAWN","sponsor":"Health Clinics Limited","startDate":"2022-05-23","conditions":"Cancer, Overall Survival","enrollment":""},{"nctId":"NCT05412056","phase":"PHASE2, PHASE3","title":"Metformin to Prevent Preterm Birth in Twin Pregnancy","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2022-06","conditions":"Preterm Birth, Premature Obstetric Labor, Twin; Complicating Pregnancy","enrollment":790},{"nctId":"NCT03608358","phase":"PHASE3","title":"Safety and Efficacy of Dapagliflozin in Asian T2DM Subjects With Inadequate Glycemic Control on Metformin/Saxagliptin","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2019-02-27","conditions":"Type 2 Diabetes Mellitus","enrollment":41},{"nctId":"NCT05326490","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of PB-201 in Type 2 Diabetic Mellitus Patients With Poor Glycemic Control Via Metformin Hydrochloride Monotherapy","status":"UNKNOWN","sponsor":"PegBio Co., Ltd.","startDate":"2022-05-30","conditions":"Type 2 Diabetes Mellitus","enrollment":546},{"nctId":"NCT04829903","phase":"NA","title":"Dulaglutide Versus Liraglutide in Obese Type 2 Diabetic Adolescents Using Metformin","status":"COMPLETED","sponsor":"Corporacion Parc Tauli","startDate":"2020-01-02","conditions":"Type 2 Diabetes Treated With Insulin, Obesity, Adolescent Obesity","enrollment":116},{"nctId":"NCT01775813","phase":"PHASE4","title":"The Health Influences of Puberty (HIP) Study","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2011-06","conditions":"Obesity, Insulin Resistance, Gonadal Dysfunction","enrollment":104},{"nctId":"NCT01725490","phase":"PHASE2","title":"The Chemopreventive Effect of Metformin in Patients With Familial Adenomatous Polyposis: Double Blinded Randomized Controlled Study","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2013-02-15","conditions":"Familial Adenomatous Polyposis","enrollment":34},{"nctId":"NCT02911948","phase":"PHASE3","title":"A Double-blinded Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec Both in Combination With Metformin in Japanese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal or Pre-mix/Combination Insulin Therapy and Oral Anti-diabetic Drugs","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2016-09-21","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":210},{"nctId":"NCT04817215","phase":"PHASE3","title":"Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus","status":"UNKNOWN","sponsor":"King Hamad University Hospital, Bahrain","startDate":"2021-10","conditions":"Diabetes Mellitus, Type 2","enrollment":608},{"nctId":"NCT03053518","phase":"NA","title":"Validation of Machine Learning Based Personalized Nutrition Algorithm to Reduce Postprandial Glycemic Excursions Among North American Individuals With Newly Diagnosed Type 2 Diabetes","status":"TERMINATED","sponsor":"NYU Langone Health","startDate":"2017-06-30","conditions":"Type2 Diabetes","enrollment":22},{"nctId":"NCT03907202","phase":"PHASE1","title":"A Clinical Study to Evaluate the Safety, Tolerability, PK, PD, and Efficacy of KBP-089 in Patients With T2DM","status":"TERMINATED","sponsor":"KeyBioscience AG","startDate":"2018-04-17","conditions":"Type II Diabetes Mellitus","enrollment":25},{"nctId":"NCT03349684","phase":"PHASE3","title":"Loose-dose Combination of Acarbose and Metformin for T2DM in Metformin-failure Patients","status":"COMPLETED","sponsor":"Bayer","startDate":"2018-03-05","conditions":"Diabetes Mellitus, Type 2","enrollment":287},{"nctId":"NCT02419612","phase":"PHASE3","title":"A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-08-14","conditions":"Diabetes","enrollment":444},{"nctId":"NCT04065581","phase":"PHASE1","title":"Bioequivalence Study for Acarbose/Metformin FDC","status":"COMPLETED","sponsor":"Bayer","startDate":"2019-10-14","conditions":"Diabetes Mellitus, Type 2","enrollment":24},{"nctId":"NCT01648582","phase":"PHASE3","title":"A Study Comparing the Effects and Safety of Dulaglutide With Insulin Glargine in Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-07","conditions":"Type 2 Diabetes Mellitus","enrollment":774},{"nctId":"NCT01999218","phase":"PHASE3","title":"Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-12-16","conditions":"Type 2 Diabetes Mellitus","enrollment":1326},{"nctId":"NCT02373865","phase":"PHASE4","title":"Risk of Nocturnal Hypoglycemia and Arrhythmias With Sitagliptin Versus Glimepiride in Patients With Type 2 Diabetes","status":"TERMINATED","sponsor":"GWT-TUD GmbH","startDate":"2015-09","conditions":"Diabetes Mellitus Type 2","enrollment":4},{"nctId":"NCT02630706","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Ertugliflozin in Asian Participants With Type 2 Diabetes and Inadequate Glycemic Control on Metformin Monotherapy (MK-8835-012)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-12-16","conditions":"Type 2 Diabetes Mellitus","enrollment":506},{"nctId":"NCT01059825","phase":"PHASE2","title":"Study Of Safety And Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-016)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-02-24","conditions":"Diabetes Mellitus, Type 2","enrollment":375},{"nctId":"NCT02036515","phase":"PHASE3","title":"Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006; VERTIS SITA2)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-03-12","conditions":"Type 2 Diabetes Mellitus","enrollment":464},{"nctId":"NCT02099110","phase":"PHASE3","title":"Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-04-22","conditions":"Type 2 Diabetes Mellitus","enrollment":1233},{"nctId":"NCT01755156","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy (MK-3102-024)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-01-11","conditions":"Type 2 Diabetes Mellitus","enrollment":402},{"nctId":"NCT01697592","phase":"PHASE3","title":"Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-10-24","conditions":"Type 2 Diabetes Mellitus","enrollment":585},{"nctId":"NCT01717313","phase":"PHASE3","title":"A Study to Assess the Safety and Efficacy of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control (MK-3102-011)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-12-05","conditions":"Type 2 Diabetes Mellitus","enrollment":329},{"nctId":"NCT01217073","phase":"PHASE2","title":"A Dose-Range Finding Study in Participants With Type 2 Diabetes (MK-3102-006)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-10-08","conditions":"Type 2 Diabetes Mellitus","enrollment":685},{"nctId":"NCT02033889","phase":"PHASE3","title":"A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007).","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-12-13","conditions":"Type 2 Diabetes Mellitus","enrollment":621},{"nctId":"NCT02284893","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-09-09","conditions":"Type 2 Diabetes","enrollment":461},{"nctId":"NCT01620593","phase":"PHASE2","title":"Castration Compared to Castration Plus Metformin as First Line Treatment for Patients With Advanced Prostate Cancer","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2011-04","conditions":"Prostate Cancer","enrollment":41},{"nctId":"NCT02546609","phase":"PHASE2","title":"The Effect Of NS-0200 Versus Placebo On Hepatic Fat Content In Patients With Non Alcoholic Fatty Liver Disease","status":"COMPLETED","sponsor":"NuSirt Biopharma","startDate":"2015-11-19","conditions":"NAFLD","enrollment":91},{"nctId":"NCT01958671","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Ertugliflozin Monotherapy in the Treatment of Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Diet and Exercise (MK-8835-003, VERTIS MONO)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-10-09","conditions":"Type 2 Diabetes Mellitus","enrollment":461},{"nctId":"NCT02022007","phase":"PHASE3","title":"Saxagliptin + Metformin Compared to Saxagliptin or Metformin Monotherapy in PCOS Women With Impaired Glucose Homeostasis","status":"COMPLETED","sponsor":"Woman's","startDate":"2014-03","conditions":"Polycystic Ovary Syndrome, Disorder of Glucose Regulation","enrollment":38},{"nctId":"NCT00722371","phase":"PHASE3","title":"MK0431 and Pioglitazone Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-102 AM2)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-09-05","conditions":"Type 2 Diabetes Mellitus","enrollment":1615},{"nctId":"NCT01028391","phase":"PHASE3","title":"30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-09-01","conditions":"Type 2 Diabetes Mellitus","enrollment":317},{"nctId":"NCT00086515","phase":"PHASE3","title":"Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-020)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-06-30","conditions":"Diabetes Mellitus, Type II","enrollment":701},{"nctId":"NCT01517373","phase":"PHASE2","title":"Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-02","conditions":"Diabetes Mellitus, Type 2","enrollment":304},{"nctId":"NCT01475461","phase":"PHASE2","title":"Phase 2 Study To Evaluate Safety And Efficacy Of Investigational Drug - PF04937319 In Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-11","conditions":"Type 2 Diabetes Mellitus","enrollment":345},{"nctId":"NCT00000620","phase":"PHASE3","title":"Action to Control Cardiovascular Risk in Diabetes (ACCORD)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1999-09","conditions":"Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia","enrollment":10251},{"nctId":"NCT01425580","phase":"PHASE2","title":"Liraglutide and Heart Failure in Type 2 Diabetes","status":"COMPLETED","sponsor":"Thomas Nystrom","startDate":"2012-01","conditions":"Congestive Heart Failure, Type 2 Diabetes Mellitus","enrollment":62},{"nctId":"NCT00337610","phase":"PHASE3","title":"Sitagliptin Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-06","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":190},{"nctId":"NCT00374907","phase":"PHASE3","title":"A Study Assessing Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-09","conditions":"Type 2 Diabetes","enrollment":156},{"nctId":"NCT01956305","phase":"PHASE1","title":"Randomized, Placebo-controlled, 2 Period, Single-blind, Sequential, Multiple Ascending Dose Study","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2013-09","conditions":"Type 2 Diabetes Mellitus","enrollment":48},{"nctId":"NCT01728740","phase":"PHASE1","title":"Bioequivalence Study for Acarbose / Metformin FDC","status":"COMPLETED","sponsor":"Bayer","startDate":"2012-09","conditions":"Diabetes Mellitus, Type II","enrollment":40},{"nctId":"NCT01193296","phase":"PHASE4","title":"Glycemic Holter Study (Continuous Glucose Monitoring) -","status":"COMPLETED","sponsor":"Novartis","startDate":"2010-06","conditions":"Type 2 Diabetes Mellitus","enrollment":36},{"nctId":"NCT00924573","phase":"PHASE3","title":"Comparative Study of HOE490 O (Glimepiride and Metformin) Compared With Placebo on Top of Glimepiride","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-05","conditions":"Type 2 Diabetes Mellitus","enrollment":189},{"nctId":"NCT01035528","phase":"PHASE4","title":"Can Insulin Glargine Improve Myocardial Function in Patients With T2D and Coronary Artery Disease (CAD)","status":"UNKNOWN","sponsor":"Munich Municipal Hospital","startDate":"2005-04","conditions":"Coronary Artery Disease, Type 2 Diabetes","enrollment":32},{"nctId":"NCT00269061","phase":"PHASE1","title":"Study In Patients With Type 2 Diabetes Who Are Taking Metformin And Sulfonylurea, Metformin And Insulin, Or Insulin","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-01","conditions":"Non-Insulin-Dependent Diabetes Mellitus","enrollment":32},{"nctId":"NCT00182494","phase":"PHASE4","title":"Diabetes Prevention Program in Schizophrenia [DPPS]","status":"UNKNOWN","sponsor":"Hamilton Health Sciences Corporation","startDate":"2005-02","conditions":"Diabetes Mellitus, Schizophrenia","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":288,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Metformin (blinded)","genericName":"Metformin (blinded)","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Metformin reduces hepatic glucose production and improves insulin sensitivity by activating AMP-activated protein kinase (AMPK). Used for Type 2 diabetes mellitus, Prediabetes (prevention of progression to type 2 diabetes), Polycystic ovary syndrome (PCOS).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}